Medical Condition News

RSS

Study on spinal cord stem cells paves way for post stroke symptom treatment

Neuralstem, Inc. announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, "Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats," was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference

15 Sep 2010

AMRI selects compound for advanced preclinical testing in treatment of IBS

AMRI today announced the selection of a compound from its proprietary research program for the treatment of irritable bowel syndrome (IBS) for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in 2011.

15 Sep 2010

Mechanism behind gene mutation leading to development of cleft palate

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains why a certain gene mutation causes craniofrontonasal syndrome (CFNS), a disorder that causes cleft palate and other malformations in the face, brain, and skeleton. Cleft palate affects one of every 1,000 newborns. The research is published in the September 15 issue of Genes & Development.

15 Sep 2010

Medical students experience high rate of depression than general population: Study

Medical students experience depression at a higher rate than the general population and attach high levels of stigma to the mental illness, according to U-M research to be published Sept. 15 in the Journal of the American Medical Association.

15 Sep 2010

Study to assess impact of radiation exposure on multiple cancer risk

It is well known that exposure to radiation has multiple harmful effects - including causing cancer - but until now, it has been unclear to what extent such exposure increases a person's risk of developing more than one cancer. The first large-scale study of the relationship between radiation dose and risk of multiple cancers among atomic bomb survivors in Hiroshima and Nagasaki, Japan reveals a similar risk in the development of first and second subsequent cancers.

15 Sep 2010

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.

15 Sep 2010

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors

20/20 GeneSystems, Inc. announced today at ADAPT 2010, an industry meeting focusing on advancing personalized medicine, the commercial launch of their patented technology for biomarker identification in tumors and other tissue samples. 20/20 is currently offering the technology to industry and academic researchers under service contracts.

15 Sep 2010

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN).

15 Sep 2010

PLX-PAD therapy improves quality of life in CLI patients

Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

15 Sep 2010

UT Southwestern receives $8 million NIH grant to study influence of brain and liver on inflammation

An $8 million grant from the National Institutes of Health will enable UT Southwestern Medical Center to investigate how fat tissue "talks" to the brain and the liver to promote inflammation-related disorders such as diabetes, heart disease and obesity.

15 Sep 2010

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Researchers at Brown University and Women & Infants Hospital have invented the first artificial human ovary, an advance that provides a potentially powerful new means for conducting fertility research and could also yield infertility treatments for cancer patients. The team has already used the lab-grown organ to mature human eggs.

15 Sep 2010

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

Canadian Cancer Society, POGO collaborate to improve quality of life in childhood cancer survivors

The Canadian Cancer Society and the Pediatric Oncology Group of Ontario (POGO) today announced that they have joined forces to improve the quality of outcomes for children and adolescents diagnosed with cancer and their families.

15 Sep 2010

ACT receives patent for RPE cells to treat retinal degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

USF receives grant for studying ways to protect fetal brain from maternal infection

University of South Florida (USF) neuroscientists have been awarded a $400,000 federal grant to study ways of protecting the developing fetal brain from the damaging effects of maternal infections, a suspected cause for certain types of autism.

15 Sep 2010

Researchers identify risk gene for schizophrenia

An international team of researchers has identified a risk gene for schizophrenia, including a potentially causative mutation, using genome-wide association data-mining techniques and independent replications.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Medical Condition News

Study on spinal cord stem cells paves way for post stroke symptom treatment

AMRI selects compound for advanced preclinical testing in treatment of IBS

Mechanism behind gene mutation leading to development of cleft palate

Medical students experience high rate of depression than general population: Study

Study to assess impact of radiation exposure on multiple cancer risk

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Heart patients with Type D personality at higher risk of future cardiovascular problems

20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

PLX-PAD therapy improves quality of life in CLI patients

UT Southwestern receives $8 million NIH grant to study influence of brain and liver on inflammation

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Mechanism linking brain activity to sleep discovered

Canadian Cancer Society, POGO collaborate to improve quality of life in childhood cancer survivors

ACT receives patent for RPE cells to treat retinal degeneration

microRNA 451 enhances treatment response in stomach cancer patients: Research

USF receives grant for studying ways to protect fetal brain from maternal infection

Researchers identify risk gene for schizophrenia

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News